Navigation Links
PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
Date:4/7/2009

hospitals and clinics are cutting back their spending on surgical devices and patients are postponing elective procedures, we have seen significant uptake of the PlasmaBlade by surgeons," said John Tighe, president and chief executive officer of PEAK Surgical. "The fact that in just eight months, more than 1,000 patients have undergone surgical procedures with the PlasmaBlade is a testament to the benefits the technology provides to surgeons and patients, including improved surgical incision healing, minimal bruising, scarring and inflammation."

"The PlasmaBlade technology has been extensively validated through preclinical data, and I expect that the comprehensive clinical study program under way will confirm the positive patient outcomes we are seeing clinically," said Dr. Howard Rosenberg, former chief of surgery at El Camino Hospital in Mountain View , Calif., and co-primary investigator of the PRECISE abdominoplasty study.

Since the PEAK Surgery System was cleared by the U.S. Food and Drug Administration for use in general surgery and launched in July 2008 in the United States, PEAK Surgical has achieved several other milestones, including:

  • Introduction of two new products in the PlasmaBlade family, including the PlasmaBlade Needle, specifically designed for ultra-precise surgical procedures, and the PlasmaBlade EXT, designed for use in surgical procedures requiring an extended-reach tip;
  • Receipt of 510(k) clearance for the PEAK Surgery System to expand the indications to include cutting and coagulation of soft tissue during plastic and reconstructive, ENT (ear, nose and throat), gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures;
  • Receipt of European CE Mark approval for the PEAK Surgery System for use in general surgery.

Benefits of the PlasmaBlade and PULSAR Generator<
'/>"/>

SOURCE PEAK Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Children and Orthopaedic Surgical Emergencies
4. Novel Product for Post Surgical Scar Formation Entering Clinical Development
5. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
6. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
7. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
8. American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
9. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... four weeks for the first dose cohort, 200 mg bid, ... with pegylated interferon and ribavirin (SOC) in HCV patients. ... of virus (<15 IU/ml) at week 4, known as ... compared to 20% of patients receiving placebo plus SOC. ...
(Date:12/17/2009)... Resources, one of the world,s leading research and ... finds that over 70 percent of surveyed U.S. ... diabetes drugs with novel mechanisms of action versus ... need for additional DPP-IV inhibitors. Both surveyed physicians ... ability and physicians in particular say the most ...
(Date:12/17/2009)... Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX ) today ... President, Sales and Commercial Affairs. In this ... be responsible for all commercial activities, including pre-launch ... with the collaboration agreement between the Company and ... that emerge from the Company,s pipeline. Ms. ...
Breaking Medicine Technology:ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 1ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 2ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 3Consumers Compare Virginia HMOs on Quality and Satisfaction Scores Improve in Newest Report 59346 1Consumers Compare Virginia HMOs on Quality and Satisfaction Scores Improve in Newest Report 59346 2Walmart com Launches Health 26amp 3B Beauty Products Online for Home Delivery 59343 1Walmart com Launches Health 26amp 3B Beauty Products Online for Home Delivery 59343 2
... heavily-pretreated patients in the high dose groups achieved ... March 5 ACCESS PHARMACEUTICALS, INC. (OTCBB: ... efficacy results from its Phase 2 monotherapy clinical ... ovarian cancer patients. In this monotherapy study 66% ...
... Research Group Limited, the international pharmaceutical services group, ... submission of the New Drug Application for Acurox(R) ... Premier Research provided full service clinical trial management ... efficacy study, which was conducted at their research ...
Other Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Premier Research Announces Milestone New Drug Application 2
(Date:12/17/2009)... ANGELES, Dec. 17 Pacific ... Energy-X lip balms, today announced the launch of ... therapeutic heating/cooling treatment packs are specifically designed to ... developed in a variety of applications. Researchers behind ... a specialized corn to hold temperatures for long ...
(Date:12/17/2009)... Yoest Urges "Comprehensive Respect for Life" in Majority ... ,, WASHINGTON, Dec. 17 ... Yoest, sent a letter today to Senate Majority ... amendment - the Majority Leader,s revisions to a ... The letter urges Senator Reid to include "specific ...
(Date:12/17/2009)... it comes from physician, study finds , , THURSDAY, Dec. ... most influence in convincing parents to place infants on ... prevent sudden infant death syndrome, or SIDS, researchers have ... to Sleep" campaign in 1994, the number of infants ... from 25 percent to 70 percent, and the rate ...
(Date:12/17/2009)... down on prevention, experts say , , THURSDAY, Dec. ... are getting better at treating heart attacks and ... the basic rules for preventing them, according to ... Topping the list: too little exercise, too much ... surveyed last year reported no activity vigorous enough ...
(Date:12/17/2009)... likely to try alcohol, illegal drugs , , THURSDAY, Dec. ... cigarettes is riskier than using illicit drugs or binge ... may increase the likelihood that they,ll experiment with alcohol ... are on the right track with cigarette smoking and ... dangers of other substances," Pamela S. Hyde, administrator of ...
Breaking Medicine News(10 mins):Health News:Thermal-Aid Bears Provide Warm Comfort to Children at Penny Lane for the Holidays 2Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Doctor's Orders Influence Baby's Sleep Position 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3Health News:Teens Think Smoking More Dangerous Than Drinking, Drugs 2
... The benefits of cognitive behavior therapy (CBT) in overcoming ... researchers// at the University of Pittsburgh School of Medicine. ... the American Journal of Psychiatry, the official journal of ... to predict the response to therapy could be a ...
... those who suffer from severe urinary infection are more ... studies had found a link between acute infections and ... between infections and clotting in large veins, reported the ... Smeeth at the London School of Hygiene and Tropical ...
... have announced that two new genes found with breast tumors ... degree of accuracy//. In the report appearing in he April ... genes could help identify women at risk for an early ... gene profile was previously discovered as a potential marker of ...
... conducted by psychologists from Sheffield University most women still ... attitudes towards sex revealed that women of all ages ... is wrong. ,The women community despite achieving ... do so out of desperation or drunkenness. The research ...
... despite making in-depth analysis in the field of attention ... the children. ,As reported in foodconsumer.org, ... scientists' control, between 30 percent and 65 percent of ... that make diagnosis and treatment all the more perplexing. ...
... drinking has been challenged by a recently published study ... against cardiovascular disease. ,Previous studies have established ... day can help reduce the risk of developing cardiovascular ... of contracting some type of cancers. ,However ...
Other Medicine News:Health News:Brian Imaging Can Foretell Results Of Treating Depression 2Health News:Despite More Studies Researchers Are Still Confound With ADHD 2Health News:Moderate Drinking Does Not Guard Against Heart Disease 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: